| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Commercial Officer
1 company
Karas Eric is a Chief Commercial Officer at ARS Pharmaceuticals, Inc.. Recent SEC Form 4 filings include 0 buys and 8 sells.
Estimated insider holdings value: $359K based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 12, 2026 | SPRY Ars Pharmaceuticals, Inc. | Chief Commercial Officer | Sale+OE | 25,000 | $10.00 | $250,000.00 | -67.2% | - | - | |
| Jul 1, 2025 | SPRY Ars Pharmaceuticals, Inc. | Chief Commercial Officer | Sale+OE | 15,000 | $16.99 | $254,860.50 | -59.3% | -39.6% | - | |
| Jun 18, 2025 | SPRY Ars Pharmaceuticals, Inc. | Chief Commercial Officer | Sale+OE | 15,000 | $16.00 | $240,000.00 | -66.1% | -40.9% | -39.3% | |
| Mar 20, 2025 | SPRY Ars Pharmaceuticals, Inc. | Chief Commercial Officer | Sale+OE | 10,000 | $14.00 | $140,000.00 | -56.5% | +11.2% | -42.9% | |
| Dec 4, 2024 | SPRY Ars Pharmaceuticals, Inc. | Chief Commercial Officer | Sale+OE | 10,000 | $14.04 | $140,423.37 | -46.8% | -27.1% | -30.9% | |
| Sep 18, 2024 | SPRY Ars Pharmaceuticals, Inc. | Chief Commercial Officer | Sale+OE | 10,000 | $14.00 | $140,000.00 | -63.7% | -16.3% | -29.3% | |
| Aug 19, 2024 | SPRY Ars Pharmaceuticals, Inc. | Chief Commercial Officer | Sale+OE | 10,000 | $14.00 | $140,000.00 | -63.7% | -3.2% | -3.2% |